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A current need in Parkinson’s disease (PD) is advancing understanding on predicting risk and 
rate of PD development. A proposed method in doing is through assessing a combination of 
biomarkers and neuroimaging techniques to evaluate key pathologphysiologies within PD. 
However, neuroimaging is currently underutilised and underdeveloped in clinical PD and 
verified biomarkers are yet to be confirmed. This study aims to assess whether differences exist 
between PD and healthy controls for the structural integrity of the SN measured by MRI, along 
with measures of CSF alpha synuclein, CSF tau and serum IGF-1. In addition, whether 
biomarker levels are predictive of SN volume loss will be investigated. SN integrity was 
determined by comparing SN signal loss detected via manual masking of Axial T2-weighted 
MRI scans to two control regions: red nucleus (RN) and midbrain. Significantly higher volume 
loss was found in patients compared to controls in both the SN:RN (t (69.61) = -5.49, P = < 
0.01) and SN:midbrain (t (57.55) = -6.047; P = < 0.001). Contrastingly however, baseline 
differences in biomarker data within subjects who underwent MRI analysis yielded no 
difference between groups (P > 0.05). This was reflected in linear regression models, 
highlighting variation accounted for by biomarkers and covariates was comparable to models 
of biomarkers in isolation and in conjunction. This suggests that little additive effect exists 
between biomarkers to improve the predictive power of the model. Overall, the results are 
insufficient to draw conclusions on the predictive relationship between tested biomarkers and 







Parkinson’s Disease (PD) is a hypokinetic disorder and is the second most common 
neurodegenerative disease in the world 1-2. Currently 80,000 people live with PD in Australia 
alone, approximately 1/350 of the population2. However, this rate is expected to increase as 
prevalence has steadily risen overtime due to an aging population, making PD a global 
concern1.  
The characteristic hypokinetic symptoms of PD are bradykinesia and at least one other deficit3-
4. The presence of these cardinal motor disorders is the current standard for diagnosing patients 
with PD8-9. However, once motor symptoms present, patients have already lost 60-80% of their 
DA neurons1,3-4. This emphasises a need to develop methods of predicting PD, with one 
proposed method being targeting known pathologies of disease progression and development.  
PD pathology greatly alters the circuitry of the basal ganglia, sub-cortical nuclei highly inter-
connected with the cortex which is attributed to a variety of functions5-8. Within the context of 
PD, the most prominent function disrupted is the initiation of voluntary movement5-6. This is 
attributed to wholesale loss of dopaminergic (DA) neurons, predominantly in the Substantia 
Nigra pars compacta (SN), as shown in figure 1:5 
 
Figure 1: Ex-vivo midbrain slices comparing prominent SN in healthy (A) against 
depigmented SN in PD (B)3 
Under normal conditions, the SN produces sufficient dopamine to modulate pathways vital for 
regulating voluntary movement7-9. These include a monosynaptic direct pathway (D1) 
responsible for promoting movement and a polysynaptic indirect pathway (D2) which inhibits 
it7-8. However, PD, dopaminergic input is heavily reduced, resulting in increased activation of 
the indirect pathway, thereby inhibiting voluntary movement7. 
However, in PD, DA input is heavily reduced thereby resulting in decreased activation of the 
direct pathway7-8. Simultaneously, the inhibitory function dopamine has on the indirect 
pathway is reduced, resulting in increased activation, with the imbalance in pathways resulting 
in voluntary movement, emphasised in figure 2:7-9 
 
Figure 2: Changes to the contribution of the Direct Pathway (D1) and Indirect Pathway (D2) 
in Normal vs Parkinson’s disease5. 
Currently it is unknown what initiates the cascade of events that leads to eventual DA cell death 
and disease development10. However, many biomarkers have been identified as noticeably 
different in Parkinsonian brains10. Understanding the relationship between biomarkers and PD 
is a major focus in PD research, as their verification will allow for advances in the developing 
predictive methods.   
One prominent biomarker is the protein alpha synuclein (α-syn), acting as the pathological 
hallmark for PD1,3,11-12. While the normal function of α-syn is not well understood, it is highly 
expressed in synapses, hypothesised to interact with vesicles to provide subtle breaks in 
neurotransmitter release13. For a yet unknown reason, α-syn misfolds in PD, leading to 
aggregations known as Lewy bodies1, 11-13. These induce a neurotoxic environment through 
many proposed mechanisms such as synaptic deficits and increased oxidative stress, which can 
perpetuate DA death11-13. 
Additionally, tau proteins, involved in microtubule stabilisation within neurons, have been 
attributed to PD development-14. Hyperphosphorylation of tau leads to abnormal deposition  
and aggregations in neuronal cell bodies, leading to the development of insoluble 
neurofibrillary tangles (NFTs)14-16. While PD is not considered a typical tauopathy, evidence 
suggests that NFTs and the interaction between tau and α-syn may contribute PD 
development14 -16. It is hypothesised that accumulation of α-syn  in synapses has a positive 
relationship with tau recruitment which induces damage and reduces axonal transport 
functioning.16 This initiates a cycle of increased accumulation of said proteins which would 
eventually result in DA death.16 
Finally, interleukin growth factor (IGF-1) is a hormone with endocrine, paracrine and autocrine 
capabilities and is associated with several functions within the brain10,17-18. While little is 
known about the mechanisms that regulate IGF-1 expression in-vivo, it has many 
neurophysiological functions that may implicate in PD pathophysiology10,17-18. For example, 
one of the primary risk factors for developing PD is age and evidence shows IGF-1, having 
known neuroprotective mechanisms, decreases with age10. Additionally, males are at higher 
risk of PD as oestrogen provides women protection via IGF-110.   
Effectively verifying the use of biomarkers requires understanding their relationship with the 
hallmarks of PD, such as structural integrity of the SN. Currently, the go to standard for 
evaluating differences in SN integrity is via assessing ex-vivo sections of the midbrain7. 
Therefore, a need exists to utilise in-vivo imaging to evaluate the SN and dopaminergic system. 
However, current imaging techniques are inadequate and underdeveloped for PD diagnosis.19 
DaTscans are a form of single photon emission computerized tomography (SPECT) imaging 
technique that assesses dopamine transporters20-21. The radiopharmaceutical ioflupane is 
injected into the bloodstream where it binds to dopamine transporters within the striatum, 
whereby SPECT allows visualisation of the amount of transporter present20-21. Due to reduced 
dopamine, lower signal is reported in PD, with abnormal DaTscans and final diagnosis of PD 
being highly correlated20-21. However, it suffers from significant limitations being that it is not 
entirely sensitive to early PD20 and is unable to distinguish between other parkinsonian 
disorders21. In addition, from a patient perspective, it is both invasive and very expensive, 
reducing its benefits in a clinical setting even further22. 
Conversely, Magnetic Resonance Imaging (MRI) allows for structural imaging and therefore 
will be essential for non-invasive diagnosis of PD23-24. MRI in previous research has confirmed 
increased atrophy of key structures such as the SN23. However, it suffers from many drawbacks 
which reduce its use in clinical PD settings23-24. The primary issue is current MRI has difficulty 
assessing deep brain and subcortical structures23. This is associated with low contrast and low 
differences in spatial resolution between structures, which makes them difficult to distinguish 
and analyse23. 
Mitigating the drawbacks of current neuroimaging is essential to verifying biomarkers as 
measures of predicting PD. This is emphasised in prior literature focusing on refining methods 
of imaging the structures effected throughout PD23-25.  One primary technique involves 
measuring volume loss in the SN using T2-weighted MRI which due to DA death, is higher in 
PD patients compared to healthy individuals. Proper evaluation of the changes that occur in PD 
via neuroimaging would allow for its relationship to be evaluated with key biomarkers of PD, 
hypothesised to be predictive of SN volume loss and dopaminergic system integrity.  
Therefore, this study aims to assess whether differences exist between PD and controls for the 
structural integrity of the SN and dopaminergic system, along with measures of CSF 
biomarkers alpha synuclein, tau and serum IGF-1. In addition, the relationship between 
biomarker levels and SN volume loss in PD will be investigated. Overall, this will contribute 
to improved patient outcomes by advancing the development of a novel technique to predict 
















MATERIAL & METHODS 
Materials & Cohorts  
All information was obtained from the Parkinson’s Progression Markers Initiative (PPMI) 
international database. It is an observational clinical study with the overall goal of verifying 
biomarkers of PD development and progression and introducing them to therapeutic studies26. 
To properly evaluate said biomarkers, PPMI utilises a comprehensive set of advanced clinical, 
imaging, and biological sample data and is therefore highly appropriate for the methodology 
of this project.   
The PPMI database has approximately 2000 subjects split into multiple cohorts26. In the context 
of this study, the two following cohorts were extracted: Early PD and healthy controls, with 
approximately 400 and 200 subjects, respectively. Control subjects were defined as people 
without PD, 30 years old or older, who do not have a first-degree blood relative with PD26. 
Excluded subjects were patients who did not yield expected corresponding DaTscan data, 
referred to as “scans without evidence of a dopaminergic deficit” (SWEDD)26. Key pieces of 
data extracted for this study include: Demographic data, MRI, DaTscans and biological sample 
data.  
 
MRI Masking Protocol  
Axial T2-Weighted MRI scans were used to assess the structural integrity of the substantia 
nigra. These scans were obtained via a Siemens 3T TIM trio scanner model, with a 12 channel 
matrix head coil and an acquisition sequence of 5 minutes and 8 seconds, ensuring that phase 
encoding direction is L/R26. Selected scans were subjected to blinded manual masking (n = 32 
Control; 64 Patient) by two independent researchers. An imaging programme called FSLeyes 
was used to create blank overlays of the original image. This allowed for masks of the three 
regions of interest to be created: the SN, red nucleus (RN) and midbrain, highlighted in figure 
4:  
 
Figure 4: (A) Cropped Midbrain in Axial T2-Weighted MRI Image which has been manually 
masked (B) to distinguish the midbrain (blue), RN (red) and SN (pink) 
To ensure adequate masks were created, two variables were taken into consideration: slice 
number and contrast. A suitable slice number was chosen per image that allowed for all three 
structures’ shapes to be easily distinguished. Slice discrepancies were recorded, in which case 
the researchers would deliberate what slice number was most appropriate and repeat the 
masking process.  
Properly distinguishing regions, particularly the RN and SN, was done via only including 
voxels of considerably darker colouration. This is indicative of signal loss, with lighter voxels 
acting as a border between the two regions. Therefore, an optimal balance between brightness 
and contrast was essential to properly distinguish borders. This is particularly important in the 
context of sub-cortical imaging, as two primary issues in segmenting PD structures is low 
contrast and poor spatial resolution between structures20. 
 
Region Comparison  
The SN is the primary region of interest, as it contains A9 DA neurons, the main neuronal type 
affected during PD23-25. To properly evaluate the expected volume loss in PD, the RN and 
midbrain acted as control regions, as they are not expected to degenerate in PD. Of interest is 
that the RN possesses A10 DA neurons, which, despite being practically adjacent to the SN, is 
spared during PD for a yet unknown reason27-29. Region values were average on account of 
inter-reliability between scorers and converted into SN:midbrain (r = 0.78) and SN:RN (r = 
0.44). Ratio calculation allowed for proper evaluation of SN volume loss by accounting for 
individual differences in size in regions between subjects.  
 
DaTscan 
DaTscan data (n = 193 Control, 419 Patient) was utilised as a measure of dopaminergic system 
integrity. The data used was on the binding potential of dopamine within the mean striatum 
(globus pallidus left + right & putamen left + right). DaTscan data was used as a method of 
validating the results collected from the MRI analysis. This was determined via correlation 
analysis on each subject with MRI data and corresponding DaTscan data (n = 32 Control, 64 
Patient).   
 
Biomarkers  
For the purposes of this research, the biomarkers selected from the overall data-set included 
CSF α-syn (n = 190 Control; 414 Patient), phosphorylated tau 181 (p-tau) (n = 176 Control; 
379 Patient) and serum IGF-1 (n = 191 Control; 405 Patient). In addition, the dataset was 
restricted to assess subjects with MRI data and corresponding biomarker data: α-syn (n = 32 
Control; 64 Patient), P-tau (n = 26 control, 57 patient) and IGF-1 (n = 30 control, 63 patient). 
 
 
Baseline Differences Between Groups  
Welch two-sample t-tests were conducted on the data provided to evaluate whether differences 
exist between patients and controls. This included the SN:RN and SN:midbrain for the MRI 
analysis, complete mean striatum dataset for the DaTscans, along with separate calculations 
for the overall and restricted biomarker dataset.   
 
Assessing Relationship Between MRI Analysis and Biomarkers  
Determining whether the selected biomarkers are predictive of SN integrity was accomplished 
via linear regression. Analyses was conducted against α-syn, p-tau or IGF-1 with the 
SN:midbrain as the dependent variable, chosen due to possessing higher inter-relatability 
between scorers (r = 0.78) compared to SN:RN (r = 0.44). Scatterplots demonstrating this can 
be found in appendix 1. Key demographics were accounted for and included as covariates to 
accurately assess the relationship, including age (years), self-reported gender (male or female), 
education (years), and diagnosis (PD or control).  
To further probe the effect of diagnosis, additional linear regressions looking at the predictive 
power of each biomarker on SN signal were conducted within both the patient and control 
groups. Data was only included for subjects who had measurements for both the biomarker of 







Demographic data for the entire cohort is reported in Table 1. No significant differences (P > 
0.05) were found between patients and controls in age, education, or gender, as shown in table 
1:  
Table 1: Demographic characteristics of PD patients versus healthy controls 
Demographics PD Patients Controls t-Test p 
 N Mean ± SD N Mean ± SD t(df)  
       
Age (years) 423 (61.66 ± 10.17) 196 (60.82 ± 10.19) -0.91(335) .364 
Education (years) 423 (15.60 ± 3.05) 196  (16.04 ± 3.05) 1.92(389) .055 
Gender  423 (%) 196 (%) 0.29(377) .772 
Female 277         44.75 126         20.35   
Male 146         23.60 70         11.30   
 
 
MRI Analysis of SN Structural Integrity  
The SN was compared to two brain regions: the midbrain and RN. Ratios were created between 
the SN and the comparator control regions, where higher ratios correspond to increased signal 
loss detected within the SN, interpreted as higher levels of volume loss. High correlations 
existed for independent SN:midbrain and SN:RN values (r = 0.774) before being averaged with 
another independent evaluator to be analysed. Figure 5A represents the SN:midbrain ratio, 
showing that patients (0.142 ± 0.021) had significantly higher volume loss (t (57.55) = -6.05; 
P = < 0.001) compared to controls (0.116 ± 0.024).   
In addition, the SN:RN ratio yielded similar results, as shown in figure 5B, highlighting 
significantly higher volume loss (t (69.61) = -5.49; P = <0.001) in Patients (1.41 ± 0.23) 
compared to Controls (1.181 ± 0.23) 
 
Figure 5: Volume loss in the SN, as measured by ratios analysis with the midbrain (A) and RN 
(B), was higher in individuals with PD compared to Controls 
*** = P < 0.001 Between Patient and Control Groups 
 
DaTscan Analysis of Dopaminergic Binding Potential in Striatum  
Dopamine binding in the mean striatum was evaluated to assess the overall integrity of the 
dopaminergic system. Figure 6 demonstrates that DaTscan results were consistent with the 
MRI structural integrity analysis. Overall, patients (1.411 ± 0.72) showed significantly lower 
(t (292.80) = 24.40; P = <0.001) binding in the striatum compared to controls (2.563 ± 0.72).  
 
Figure 6: Dopaminergic System Integrity, as measured by dopamine binding potential in the 
striatum via DaTscan analysis, was lower in Patients compared to Controls 
*** = P < 0.001 Between Patient and Control Groups 
 
Correlation Between SN Structural Integrity and Dopaminergic Binding in Striatum  
In addition, as a measure of validating the results found by MRI analysis, a correlation between 
DaTscan and both ratio analyses was conducted (n = 96). Both correlation analyses yielded 
similar results as DaTscan data possessed a weak to moderate negative relationship with the 
SN:midbrain (r = -0.34) and a weak negative relationship with the SN:RN (r = -0.29), detailed 
in figure 7: 
 
Figure 7: Scatterplots highlighting the relationship between DaTscans and (A) SN:Brainstem 
and (B) SN:RN 
 
Differences in Biomarker Levels  
Baseline differences between patients and controls were analysed in three biomarkers: CSF α-
syn, CSF p-tau and serum IGF.  Figure 8A demonstrates CSF levels of α-syn (pg/mL) being 
significantly lower (2.975 (331.93), P = 0.003) in patients (1506.7 ± 32.76) compared to 
controls (1695.19 ± 54.22). Similarly, p-tau (pg/mL) results, as shown in figure 8B, 
demonstrate patients (14.87 ± 0.27) had significantly lower levels (4.550 (41.38); P = < 0.001) 
than controls (17.52 ± 0.63). Contrastingly, serum IGF-1 (ng/mL) values showed no significant 
difference (t (362.12) = -0.56, P = 0.65) between Controls (134.5 ± 4.06) and Patients (136.70 
± 2.70), as depicted in  Figure 8C.  
 
Figure 8: Mean ± SEM of (A) α-syn (B) P-tau and (C) IGF-1 in both Patients and Controls 
in Complete Dataset.  
** = P < 0.005; *** = P < 0.001 Between Patient and Control Groups  
 
Baseline differences were also calculated on a restricted dataset which only included subjects 
who had an MRI and had a corresponding biomarker of interest. Figure 9C demonstrates that 
like baseline data, serum IGF-1 (n = 30 Control, 63 Patient) showed no significant difference 
(t (54.85) =0.33, P = 0.73) between patients (5.97 ± 0.65) and controls (5.97 ± 0.65). Unlike 
the baseline data, however, Figure 9A emphasises that CSF α-syn (n = 32 Control, 64 Patient) 
in patients (1554.14 ± 158.75) was not significantly different (t (78.5) = -.49, P = 0.66) to 
controls (1565.55 ± 96.91). Likewise, Figure 9B shows that p-tau (n  = 26 Control, 57 Patients) 
in patients (5.97 ± 0.65) was not significantly different (t (39.41) = 1.14, P =0.20) to controls 
(5.97 ± 0.65).  
 
Figure 9: Mean ± SEM of (A) α-syn (B) p-tau and (C) IGF-1 in both Patients and Controls, 
restricted to subjects with both MRI analysis and corresponding biomarkers 
 
Linear Regression Models 
Linear regression was conducted with SN:midbrain as the dependent variable and the 
biomarkers of interest as independent variables, with additional covariates such as age, gender, 
education, and diagnosis added into the model. Therefore, this assessed how well levels of α-
syn, p-tau or IGF-1, in conjunction with the other key variables, could predict volume loss in 
the SN.  
Firstly, the SN:midbrain relationship with all biomarkers included was assessed (n = 96). A 
moderate positive linear relationship exists, confirmed by Pearson’s correlation coefficient (R) 
of 0.51. No significant relationships were found between SN:midbrain and any of the 
biomarkers of interest (P > 0.05). However, a significant relationship was found with diagnosis 
(P < 0.001). The slope coefficients formed the following regression equation:  
SN:midbrain = .115 ± .000 (Age) ± .007 (Gender) ± .000 (Education) ± .029 (Diagnosis) ± 
3.87-6 (α-syn) ± .000 (p-tau) ± 4.81-5 (IGF-1) 
In addition, the R2 value was 0.44, so 44% of the variation in the SN:midbrain can be explained 
by the independent variables.  
Separate linear regressions were then conducted on individual biomarkers, with covariates still 
included, producing the following outputs in table 2:  
 
Table 2: Key outcomes extracted from linear regression analyses conducted on individual 











Consistent with the results from SN:midbrain overall analysis, diagnosis was the only 
independent variable shown to have a consistent significant relationship (P < 0.001) with 
 
 
N R R2 Slope 
Coefficient 
P-value 
α-syn 96 .63 .40  
Constant  .131  
Age .000 / 
Gender .006 / 
Education .000 / 
Diagnosis .028 *** 
α-syn 1.48-6 / 
P-Tau 83 .64 .41  
Constant  .132  
Age .000 / 
Gender .007 / 
Education .000 / 
Diagnosis .029 *** 
p-tau .000 / 
IGF-1 93 .64 .41  
Constant  .118  
Age .000 / 
Gender .007 / 
Education .000 / 
Diagnosis .029 *** 
IGF-1 4.12-5 / 
volume loss. Graphs highlighting the correlation between diagnosis and each biomarker can be 
found in Appendices 2 – 5. In addition, further detail on the regression analyses outputs found 
in Appendices 6 – 8.  
Additionally, to probe the effect of diagnosis on the predictive power of the biomarkers of 
interest on SN volume, separate linear regressions were conducted within both the patient and 
control groups on the overall SN:midbrain, shown in table 3: 
 
Table 3: Key outcomes extracted from linear regressions on all biomarkers and their 
relationship with SN:midbrain within both the PD and healthy control groups. * = P < 0.05, / 
= P > 0.05 
 
In addition, linear regressions were conducted on the influence of individual biomarkers on 
















 32 .52 .27  64 43 .18  
Constant  .19    .90  
Age -.001 *  -5.04-5 / 
Gender .003 /  .012 * 
Education .001 /  .001 / 
α-syn -9.20-6 /  2.34-6 / 
p-tau .00 /  3.01-5 / 
IGF-1 .00 /  .00 * 
Table 4: Key outcomes extracted from linear regressions on individual biomarkers 
relationship with SN:midbrain within both the PD and healthy control groups. * = P < 0.05, / 
= P > 0.05 
 
For further information on the regression outputs conducted within both the Patients and 



















α-syn 32 .42 .18  64 .32 .10  
Constant  .142    .128  
Age -.001 /  .002 / 
Gender .006 /  .059 / 
Education .001 /  .018 / 
α-syn -4.82-6 /  3.16-6 / 
P-Tau 26 .44 .19  57 .31 .09  
Constant  .144    .130  
Age -.001 /  .000 / 
Gender .006 /  .010 / 
Education .001 /  .001 / 
p-tau .000 /  .000 / 
IGF-1 30 .43 .18  63 .38 .14  
Constant  .151    .096  
Age -.001 *  -1.20-5 / 
Gender .006 /  .012 * 
Education .001 /  .001 / 
IGF-1 -5.85-5 /  9.50-5 * 
DISCUSSION  
The development of non-invasive methods of predicting risk and rate of developing PD is a 
highly developing field, as presently none exist. Currently, diagnostic criteria are dependent on 
of cardinal motor symptoms, at which point patients have undergone high levels of 
deterioration of their SN and overall dopaminergic system3-4. Therefore, studies have been 
conducted to target specific pathologies which are known to contribute to DA death and could 
therefore act as biomarkers of disease progression and development10-17. Effectively, validating 
the use of such biomarkers requires adequate neuroimaging as a comparative measure, which 
is underdeveloped and underutilised in clinical PD settings19-22. Therefore, this study 
investigated such gaps via validating neuroimaging structural integrity of the SN and 
determining whether it has a relationship with potentially predictive biomarkers. Overall, the 
results of this study to not provide sufficient data to fully support the relationship of α-syn , p-
tau or IGF-1 with SN structural integrity.  
Previous studies highlight the difficulty of verifying biomarkers to assess their efficacy as 
predictive methods30-31. Therefore, this study aimed to address this via assessing its relationship 
with T2-weighted MRI analysis. Previous findings show T2-weighted MRI can successfully 
evaluate atrophy of structures susceptible to dopaminergic loss in PD, primarily the SN23-24. 
Baseline MRI data supported this, as this study showed significantly lower ratios for patients 
compared to controls in both SN:midbrain and SN:RN, indicative of higher volume loss 
patients (Figure 5). In addition, linear regressions with diagnosis included as a covariate 
consistently showed that diagnosis possessed a significant relationship with SN:midbrain 
(Table 2). This demonstrates that the methodology employed throughout this study was an 
effective measure of evaluating SN volume loss. However, previous studies support the idea 
of employing a multi-modal imaging approach to validate and improve the translatability of 
imaging data32-33. To address this, DaTscan data was used to evaluate the dopaminergic system 
integrity to act as a comparative measure against MRI . Results showed significantly lower 
levels of dopaminergic binding in the striatum in PD compared to controls (Figure 6). DaTscans 
on their own do not provide sufficient evidence to diagnose PD as they cannot distinguish 
between other disorders with prominent dopaminergic loss20-21.  However, it has reported 
success in confirming diagnosis, particularly in patients who exhibit atypical clinical 
symptoms, making it a potentially valid measure to confirm MR-20. This was partially 
supported by the results as both the SN:RN and SN:Brainstem possessed a negative relationship 
with DaTscan analysis; however, the correlations were only weak to moderate (figure 7).  
Evaluating baseline differences in selected biomarkers using the entire PPMI database yielded 
significantly lower levels of CSF α-syn and p-tau in PD patients compared to controls (figure 
7A & 7B). This is consistent with literature, attributing lowered levels in CSF due to 
aggregations, forming Lewy bodies and NFT’s for α-syn and p-tau, respectively11-16. Lewy 
body pathology has been heavily researched due to being the pathological hallmark of PD, 
highly contributing to dopaminergic death in the SN by inducing neurotoxicity1,12-13.  Previous 
studies have shown that CSF levels of α-syn are lower in patients compared to healthy controls, 
which is reflected on the baseline differences of alpha synuclein on the overall dataset33-36. 
However, many disorders share this pathology contributing to disease progression, including 
dementia with Lewy bodies (DLB) and Alzheimer’s disease (AD)33-36. Therefore, research into 
the efficacy of using CSF biomarkers to provide differential diagnosis between disorders is 
essential. Currently, previous literature shows that α-syn can provide differentiation between 
PD and AD33-36. However, it struggles to distinguish between other Parkinsonian disorders and 
Dementia with Lewy Bodies33-36. This highlights the disadvantages of using single biomarkers 
in distinguishing PD and the need to use other validated biomarkers in conjunction 11, 37. 
Therefore, the potential of using p-tau as a complimentary biomarker is highly promising.  
While PD is not a traditional tauopathy, research has shown increasing evidence to support the 
role of p-tau and α-syn interactions in disease progression14-15. It is suggested that α-syn  and 
phosphorylated tau have synergistic effects that perpetuate neurotoxicity. In fact, p-tau has 
been found that NFTs can be found surrounding Lewy bodies, supporting the interactive 
mechanisms of α-syn and p-tau14-15. Because of this, p-tau is a heavily researched PD 
biomarker, with previous literature highlighting CSF levels of p-tau being lower in PD 
compared to controls, consistent with the baseline data within this study38-39. However, 
similarly to α-syn, it cannot make a distinction between other disorders, such as multiple system 
atrophy or progressive supranuclear palsy38-39.Therefore expanding the usefulness of assessing 
biomarkers in conjunction should include biomarkers representative of other pathologies that 
contribute to PD. 
Lewy body pathology could also be attributed to changes in specific hormone expressions 
throughout the brain. A prime example is IGF-1, a known protective factor against α-syn  
aggregation, with lower IGF-1 levels at early PD being associated with worse outcomes such 
as hastened disease progression39-41. Therefore, changes in IGF-1 expression could contribute 
to the PD development. In this study, it was found that serum IGF-1 levels were not 
significantly different in PD patients compared to healthy controls  (Figure 8C). This is 
consistent with previous literature which highlight IGF-1 being higher in moderate PD but 
indistinguishable in early PD, while others show no significant differences between PD and 
controls at all39-41.  Serum IGF-1 has reportedly limited success as a potential biomarker for 
various reasons. For example, subjects exhibit high inter- and intraindividual variability39-41. 
Also, unlike CSF biomarkers, serum IGF-1 may not be truly reflective of the changes in central 
pathophysiolog41. However, studies have shown similar expression of CSF and serum IGF-1 
within PD patients, therefore, future studies should test the efficacy of utilising CSF IGF-1 to 
improve translatability42-43.  
Baseline differences of biomarkers were also conducted on a restricted dataset which only 
included subjects with MRI analysis (figure 8). Contrary to the previous baseline data results, 
no significant differences were found across any biomarkers. This may be due to the 
significantly smaller sample size, resulting in an underpowered dataset. This is reported in 
previous literature, highlighting lack of power as a significant barrier in verifying differences 
in biomarkers across diseases44-45.  
In fact, underpowered data may drive the relationships between biomarkers and SN volume 
loss determined via linear regression. Models on overall SN:midbrain highlighted that a large 
percentage of the variation in SN:midbrain could be attributed to the independent variables. 
However, no significant relationships were found in any biomarkers. This was supported by 
models with each biomarker in isolation predicting very similar variance, indicating that little 
additive effect exists to improve the predictive power of the model. This is reflected in previous 
studies as while biomarker research has progress in identifying potential biomarkers via 
baseline differences, no fully validated biomarker is yet available for PD46-47.  
Additionally, the models distinguishing patients from Controls resulted in much lower R2 
scores. This could be attributed to both omitting diagnosis as an independent variable, 
indicating it accounted for majority of the variation, and a further reduced sample size. Like 
the complete cohort model, neither α-syn or p-tau were significantly different. However, in PD, 
IGF-1 was a significant predictor of SN:midbrain, whereas this was not present control group, 
indicating that IGF-1 contributed to volume loss of the SN noted in patients. However, due to 
the low sample size and contrast results between IGF-1 baseline and linear regression data, it 
may be that the results are not truly representative. Therefore, definitive conclusions cannot be 
drawn, and future research will need to assess the predictive power of IGF-1 in a larger dataset. 
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Appendix 4: Relationship between Diagnosis with IGF-1 
 







Appendix 6: SN:Brainstem Α-syn Linear Regression Coefficient Outputs 
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Appendix 11 - SN:Brainstem IGF-1 – PD – Linear Regression Coefficient Outputs 
 
Appendix 12 - SN:Brainstem - Α-syn – Control – Linear Regression Coefficient Outputs 
 
Appendix 13 – SN:Brainstem – Ptau – Control – Linear Regression Coefficient Outputs 
  
Appendix 14 – SN:Brainstem – IGF-1 – Control – Linear Regression Coefficient Outputs 
 
 
